Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2

Technology appraisal guidance
Reference number: TA257
Published: 27 June 2012

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix A - RPP decision paper - August 2015

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix A - RPP decision paper - August 2015

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix A - RPP decision paper - August 2015
13 August 2015
(69.29 Kb 20 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 11 August 2015